Enhancing drug-drug Interaction Prediction by Integrating Physiologically-Based Pharmacokinetic Model with Fraction Metabolized by CYP3A4

被引:2
|
作者
Jiang, Pin [1 ]
Chen, Tao [2 ]
Chu, Lin-Feng [1 ]
Xu, Ren-Peng [1 ]
Gao, Jin-Ting [3 ]
Wang, Li [3 ]
Liu, Qiang [3 ]
Tang, Lily [3 ]
Wan, Hong [1 ]
Li, Ming [4 ]
Ren, Hong-Can [3 ]
机构
[1] Shanghai Medicilon Inc, Dept DMPK, 585 Chuanda Rd, Shanghai 201299, Peoples R China
[2] Shanghai PharmoGo Co Ltd, Shanghai, Peoples R China
[3] GenFleet Therapeut Shanghai Inc, Drug Discovery Dept, 1206 Zhangjiang Rd, Suite A, Shanghai 201203, Peoples R China
[4] Zhengzhou Univ, Dept Cardiovasc Surg, Affiliated Hosp 1, 1 Jianshe Rd, Zhengzhou 450000, Peoples R China
关键词
Drug-drug interaction; PBPK; fraction metabolized; CYP inhibition;
D O I
10.1080/17425255.2023.2263358
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Enhancing the precision of drug-drug interaction (DDI) prediction is essential for improving drug safety and efficacy. The aim is to identify the most effective fraction metabolized by CY3A4 (fm) for improving DDI prediction using physiologically based pharmacokinetic (PBPK) models.Research Design and Methods: The fm values were determined for 33 approved drugs using a human liver microsome for in vitro measurements and the ADMET Predictor software for in silico predictions. Subsequently, these fm values were integrated into PBPK models using the GastroPlus platform. The PBPK models, combined with a ketoconazole model, were utilized to predict AUCR (AUCcombo with ketoconazole/AUCdosing alone), and the accuracy of these predictions was evaluated by comparison with observed AUCR.Results: The integration of in vitro fm method demonstrates superior performance compared to the in silico fm method and fm of 100% method. Under the Guest-limits criteria, the integration of in vitro fm achieves an accuracy of 76%, while the in silico fm and fm of 100% methods achieve accuracies of 67% and 58%, respectively.Conclusions: Our study highlights the importance of in vitro fm data to improve the accuracy of predicting DDIs and demonstrates the promising potential of in silico fm in predicting DDIs.
引用
收藏
页码:721 / 731
页数:11
相关论文
共 50 条
  • [41] DEVELOPMENT OF A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR BALOVAPTAN AND ITS MAJOR METABOLITE TO EVALUATE THEIR CYP3A4-MEDIATED VICTIM DRUG-DRUG INTERACTION (DDI) LIABILITY
    Olivares-Morales, A.
    Barter, Z.
    Amponsah, A.
    Bissantz, C.
    Derks, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S103 - S103
  • [42] Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software
    Marsousi, Niloufar
    Desmeules, Jules A.
    Rudaz, Serge
    Daali, Youssef
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2018, 39 (01) : 3 - 17
  • [43] A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus Host Disease Patients
    Gerner, Bettina
    Aghai-Trommeschlaeger, Fatemeh
    Kraus, Sabrina
    Grigoleit, Goetz Ulrich
    Zimmermann, Sebastian
    Kurlbaum, Max
    Klinker, Hartwig
    Isberner, Nora
    Scherf-Clavel, Oliver
    PHARMACEUTICS, 2022, 14 (12)
  • [44] Evaluation of the drug-drug interaction potential of treosulfan using a physiologically-based pharmacokinetic modelling approach
    Schaller, Stephan
    Martins, Frederico S.
    Balazki, Pavel
    Bohm, Sonja
    Baumgart, Joachim
    Hilger, Ralf A.
    Beelen, Dietrich W.
    Hemmelmann, Claudia
    Ring, Arne
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (04) : 1722 - 1734
  • [45] Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach
    Hanley, Michael J.
    Yeo, Karen Rowland
    Tugnait, Meera
    Iwasaki, Shinji
    Narasimhan, Narayana
    Zhang, Pingkuan
    Venkatakrishnan, Karthik
    Gupta, Neeraj
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (04): : 624 - 637
  • [46] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING CORRECTLY PREDICTS LACK OF CYP3A-MEDIATED DRUG-DRUG INTERACTION BETWEEN LENVATINIB AND MIDAZOLAM.
    Schuck, E.
    Yu, Y.
    Lai, G.
    Aluri, J.
    Reyderman, L.
    Shumaker, R.
    Ferry, J.
    Hussein, Z.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S49 - S49
  • [47] Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam
    Britz, Hannah
    Hanke, Nina
    Volz, Anke-Katrin
    Spigset, Olav
    Schwab, Matthias
    Eissing, Thomas
    Wendl, Thomas
    Frechen, Sebastian
    Lehr, Thorsten
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (05): : 296 - 307
  • [48] A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways
    Maïlys De Sousa Mendes
    Gabrielle Lui
    Yi Zheng
    Claire Pressiat
    Deborah Hirt
    Elodie Valade
    Naïm Bouazza
    Frantz Foissac
    Stephane Blanche
    Jean-Marc Treluyer
    Saik Urien
    Sihem Benaboud
    Clinical Pharmacokinetics, 2017, 56 : 537 - 550
  • [49] Investigation of the Impact of CYP3A5 Polymorphism on Drug-Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling
    He, Qingfeng
    Bu, Fengjiao
    Zhang, Hongyan
    Wang, Qizhen
    Tang, Zhijia
    Yuan, Jing
    Lin, Hai-Shu
    Xiang, Xiaoqiang
    PHARMACEUTICALS, 2021, 14 (03) : 1 - 15
  • [50] A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways
    Mendes, Mailys De Sousa
    Lui, Gabrielle
    Zheng, Yi
    Pressiat, Claire
    Hirt, Deborah
    Valade, Elodie
    Bouazza, Naim
    Foissac, Frantz
    Blanche, Stephane
    Treluyer, Jean-Marc
    Urien, Saik
    Benaboud, Sihem
    CLINICAL PHARMACOKINETICS, 2017, 56 (05) : 537 - 550